Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rusvinoxidase is an L-amino acid oxidase (LAAO) purified from the venom of the Russell's viper (Daboia russelii russelii).[1][2][4] It is an acidic monomeric glycoprotein (~57 kDa) that induces apoptosis in certain human cancer cell lines (e.g., MCF-7 breast cancer and Colo-205 colorectal cancer) but shows differential cytotoxicity depending on the cellular environment.[1][2][4] Rusvinoxidase promotes apoptosis predominantly via the extrinsic (death-receptor, caspase-8-mediated) and intrinsic (mitochondrial, ROS-dependent) pathways, leading to ROS generation, glutathione depletion, catalase activity reduction, mitochondrial depolarization, chromatin condensation, and activation of effector caspases.[1][2][4][9] It downregulates anti-apoptotic proteins (Bcl-xL, HSP-90, HSP-70) and increases pro-apoptotic proteins (Bax), causing cytochrome c release and caspase activation.[4][9] Rusvinoxidase is non-toxic in mice at tested doses, suggesting potential for anticancer drug development.[4][13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rusvinoxidase.